Analyzing 111 (NASDAQ:YI) & Tempus AI (NASDAQ:TEM)

111 (NASDAQ:YI) and Tempus AI (NASDAQ:TEM) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Volatility & Risk

111 has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Tempus AI has a beta of 3.54, suggesting that its share price is 254% more volatile than the S&P 500.

Profitability

This table compares 111 and Tempus AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
111	-1.01%	N/A	-4.86%
Tempus AI	-17.77%	-50.28%	-10.33%

Institutional & Insider Ownership

21.3% of 111 shares are held by institutional investors. Comparatively, 24.2% of Tempus AI shares are held by institutional investors. 43.9% of 111 shares are held by company insiders. Comparatively, 24.3% of Tempus AI shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for 111 and Tempus AI, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
111	1	0	0	0	1.00
Tempus AI	2	9	11	0	2.41

Tempus AI has a consensus target price of $71.84, suggesting a potential upside of 5.67%. Given Tempus AI’s stronger consensus rating and higher possible upside, analysts clearly believe Tempus AI is more favorable than 111.

Valuation & Earnings

This table compares 111 and Tempus AI”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
111	$1.80 billion	0.02	-$9.65 million	($1.60)	-1.94
Tempus AI	$1.43 billion	8.57	-$245.03 million	($1.44)	-47.22

111 has higher revenue and earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than 111, indicating that it is currently the more affordable of the two stocks.

About 111

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.

About Tempus AI

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.